Our vision is to be a dynamic hemispheric innovation hub for knowledge translation and commercialization of research discoveries that improve the lives of our local, national and international communities.

Our mission is to improve public health and quality of life through life-long education, experiential learning, innovative research and real-world translation of novel ideas and innovations.
Over the past 5 years (FY17-21):
- 586 innovation disclosures
- 391 US patents submitted (205 new), 74 issued
- 115 licenses, 28 options
- 28 startups
  - licensed UM IP for first time
- From 136 to 212 active agreements
- From $10.6M to $20.3M IP revenue

Cumulative startup metrics
- 100 startups, 70 that licensed UM IP
- 2 IPOs
- 1 acquisition by major company
UNIQUE RESOURCES - THE LAUNCH PAD

- 13 years in operation
  - 5500+ Student & Alumni Clients
  - 550+ Companies formed
  - 3500+ Ideas pitched
  - replicated in 27 schools
  - The Launch Pad Med

- Mentorship and guidance free for life
  - Events and Workshops
  - Concept Validation
  - Business Plan Help
  - Financial Modeling
  - Marketing / Growth Strategy
  - Idea to Monetization Accelerator

BUILDING THE INNOVATION ECOSYSTEM
Established with a grant from the W. H. Coulter Foundation
Aiming for investable technology
Funding + Bus Dev + Regulatory
  o 52 completed projects, 9 ongoing
  o largest UM licensing deal to big pharma to date
  o 1/3 UM startups out of Coulter projects
$4.95 M project expenditures
$541.2 M follow on funding
  o 87% private

<table>
<thead>
<tr>
<th>Total Follow-On</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic</td>
</tr>
<tr>
<td>$482,760,080</td>
</tr>
<tr>
<td>Diagnostic</td>
</tr>
<tr>
<td>$53,716,241</td>
</tr>
<tr>
<td>Drug Discovery</td>
</tr>
<tr>
<td>$2,636,067</td>
</tr>
<tr>
<td>Healthcare IT</td>
</tr>
<tr>
<td>$2,170,329</td>
</tr>
<tr>
<td>TOTAL</td>
</tr>
<tr>
<td>$541,282,717</td>
</tr>
</tbody>
</table>
UNIQUE RESOURCES – CONVERGE MIAMI

- External Facing / Collaboration
- Partnership with Wexford Biosciences
- Collaboration with the Cambridge Innovation Center
- Heart of an emerging Innovation District
  - 200K sf building fully occupied
  - >150 startups of all types
  - unique to Converge - wet lab space
  - Opportunity Zone
  - Master Planning under way for building 2

University of Miami steps up innovation strategy and renames life science park
The only University of Miami affiliated angel investment network.

The ‘Cane Angel Network aims to bring together entrepreneurs and investors from the University community, including students, alumni, parents, faculty and staff, to provide early-stage funding and a network of advisors.

Experiential learning for graduate students who work with the managing director to analyze startup submissions.
‘Cane Angels Promoting UM’s Vision for Growth

Initial Vetting
- ‘CAN is run as an investment firm:
  - 20-person analyst team;
  - rigorous analyst training program.
- Over 100 startups expected to apply in 2021
  - Up from 40 since ‘CAN launched in May 2020.
- The ‘CAN analyst team is a resource for both entrepreneurs and investors.

‘Investor Ready’
- We work with startups every step of the way to:
  - refine their pitch
  - hone their business model.
- Only the best of these companies are presented to investors
  - 5 have made the cut so far.
- We are here to help make investors money:
  - We don’t perform, they don’t come back.

Miami Tech Hub
- ‘CAN is working to advance Miami and UM’s position as a TechHub by:
  - Training talent
  - Supporting deals
- An example is our Fall 2021 ‘CAN initiative with Softbank:
  - 12-week, hands-on program in conjunction with Softbank executives.
  - Practical experience for the next-gen world.
Entrepreneurship, Education, Mentoring - Collaborative Support for *Start-Ups

- **The Launch Pad**
  - The Launch Pad Med
  - Information and mentoring
  - Idea to Monetization

- **WHCC**
  - Entrepreneurs in Residence
  - Startup events
  - Guidance for SBA grants
  - Concept to Commercialization
  - Seminars & other Events

- **OTT**
  - License, Option, and related agreements

- **Cane Angel Network**
  - Angel funding for U related, early-stage companies

- **Converge Miami**
  - U Innovation team suite
  - Company address
  - Co-working space
  - Rent-a-Bench in Converge Labs

- **Startup Practicum**
  - Legal support

- **i-Corps**
  - SOM CTSI, COE
  - Customer focus

- **Small Business Administration**
  - SBIR, STTR grants

- **U Innovation**
  - Courses, startup competition

**Collaborative Support for Start-Ups**

*UK Innovations,* Miami, Florida, USA
I. GENERAL

I. DEFINITIONS and ABBREVIATIONS

Applicable Personnel: all full- and part-time faculty, staff and employees, students, fellows and non-employees who use University funds, facilities or other resources, or participate in University-administered research, including visiting faculty and industrial personnel, regardless of obligations to other companies or institutions.

III. OWNERSHIP

Creations vs Innovations

IV. ADMINISTRATION OF THE POLICY

V. DISCLOSURE, REVIEW AND PROTECTION OF INNOVATIONS

Public disclosure can preclude patenting. Innovations should be disclosed early for optimal impact.

VI. DISTRIBUTION OF REVENUE DERIVED FROM COMMERCIALIZATION OF INNOVATIONS

The U negotiates a share and should revenue return to the U, it is shared with inventors, departments and schools.
Effective tech transfer can lead to
- licensing to major companies
- sponsored research
- IP revenue to inventors and departments

Disclose your innovations to OTT
- avoid public disclosure until you do so
- OTT will assess disclosure
  - patentable?
  - copyright, trademark, trade secret?
  - license to established company or a startup?

An anti-CD30 specific monoclonal antibody developed by Dr. Eckhard Podack in 1992; licensed to Seattle Genetics in 1999

Led to the development of Adcetris, the first new treatment in years for CD30-positive lymphomas

This work was supported by grants from the National Institutes of Health (R01 DK93866), the Wallace H. Coulter Center, the Diabetes Research Institute, and the American Diabetes Association and by a sponsored research agreement from Bristol-Myers Squibb.

Dr. Azorides Morales and colleagues created a revolutionary new way to test tissue samples so that patients learn the results of cancer and other tissue biopsies in just one hour

Technology was licensed to Sakura, which is selling the Tissue Xpress devices worldwide
UM Startups

Heat Biologics
Cancer rx, IPO 07-29-13

PELICAN Therapeutics
A Division of Heat Biologics
Cancer therapeutics

RMP
Management of excessive bleeding

priZmTx
Ultra-rare pediatric orphan diseases

AEGLE Therapeutics
Inflammatory diseases

VIGILANT BIOSCIENCES
Early dx oral and oropharyngeal cancer

TruviTech
Tech platform to transform drug discovery

Ambulero
Regenerative cell and gene therapies

ZyVersa
Inflammatory and renal diseases

heru
AI driven dx, personalized vision care

LONGEVERON Cell-Based Therapies
Aging-related diseases & conditions
IPO 02-11-21

HealthSnap
Remote Patient Monitoring

WALDENCIOSCIENCE
Renal disease; formerly Trisaq Inc; Walden
formed with $51M from Arch Ventures
Contacts and Information

UM Vice Provost for Innovation, Chief Innovation Officer Miller School of Medicine
Norma Kenyon, PhD
nkenyon@miami.edu

Office of Technology Transfer: techtransfer@med.miami.edu
Director: Bin Yan, PhD, JD; byan@miami.edu

The Launch Pad: hello@thelaunchpad.org
Director: Brian Breslin, MBA; brb99@miami.edu

'Cane Angel Network: caneangelinfo@miami.edu
Managing Director: Jeffrey Camp; j.camp@miami.edu

Wallace H. Coulter Center: coulter@med.miami.edu
William Silverman, PhD, MBA; w.silverman@miami.edu

UNIVERSITY OF MIAMI POLICY ON INVENTIONS, INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER:
https://fs.miami.edu/_assets/pdf/facultysenate/Documents/FacultyManual.pdf; pages 171-180

U Innovation website: https://innovation.miami.edu/index.html